Isomorphic Labs raises $5B, joining AI’s pharma wave with Sequoia and a16z backing

The valuation—nearly double the $2.5 billion Nuvacore secured six weeks ago—shows how fast AI-focused biotech firms are scaling, all aiming to replace traditional research with computational speed.
The round comes as Sequoia and a16z increase their bets on biotech, even though the sector’s funding environment remains unpredictable.
Isomorphic’s ability to turn its AI models into working medicines will depend on whether it can outperform traditional labs, which have spent decades refining their processes.
For investors, the round reflects a bigger trend: AI in biotech is no longer just a cost-cutting tool—it’s becoming a competitive advantage. The question is whether Isomorphic can stay ahead long enough to justify its valuation or if it will end up among the overfunded startups waiting for the next downturn to sort out the winners.
Sources: sifted.eu
“This funding surge suggests AI-driven drug discovery startups are betting on becoming acquisition targets—or IPO candidates—before the next biotech boom.”
One of the funding rounds reported in the week of 16–22 November 2026. See every round that week.
Read the original reporting
The outlets below did the original reporting.
Related briefs
- MegaRobo’s $200M Haul Leads Asia’s $335M Funding Week as Semiconductors and AI Infrastruct
- Archer Raises $10M to Fix AI’s Broken Hiring Arms Race—With a Bipartisan Platform
- AI startup Dreamteam bets $53M on CRM automation—can it outmaneuver Salesforce and SAP?
- India’s AI Funding Boom Hides a Critical Weakness: Can It Build a Foundational Player?
- BrightAI raises $97M to expand AI-driven industrial monitoring with GE Vernova partnership
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.